INT26369

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 1982
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 19
Total Number 19
Disease Relevance 5.39
Pain Relevance 1.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (S100A6) signal transduction (S100A6) nuclear envelope (S100A6)
plasma membrane (S100A6) nucleus (S100A6) cytoplasm (S100A6)
Anatomy Link Frequency
plasma 6
myometrium 1
superior 1
S100A6 (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 49 98.52 Very High Very High Very High
withdrawal 35 97.64 Very High Very High Very High
depression 28 86.16 High High
agonist 12 82.28 Quite High
headache 6 81.84 Quite High
Inflammatory response 15 81.20 Quite High
Dismenorea 7 81.12 Quite High
backache 4 78.08 Quite High
antagonist 7 75.00 Quite High
Endogenous opioid 2 75.00 Quite High
Disease Link Frequency Relevance Heat
Sepsis 44 99.24 Very High Very High Very High
Hypertension 71 98.96 Very High Very High Very High
Breast Cancer 7 96.24 Very High Very High Very High
Infection 94 95.92 Very High Very High Very High
Increased Venous Pressure Under Development 18 95.24 Very High Very High Very High
Coronary Heart Disease 3 95.20 Very High Very High Very High
Diabetes Mellitus 67 94.32 High High
Affective Disorder 2 94.16 High High
Cardiovascular Disease 9 92.88 High High
Heart Rate Under Development 32 92.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Plasma renin activity and PA levels in patients from 40 to 59 years increased significantly 90 minutes after induction, whereas PRA and PA levels in patients over 80 years were unchanged.
Gene_expression (levels) of PRA in Plasma
1) Confidence 0.65 Published 1999 Journal J Clin Anesth Section Body Doc Link 10386279 Disease Relevance 0.05 Pain Relevance 0
B activation on myometrial PRA, PRB or ER alpha expression.
Gene_expression (expression) of PRA
2) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2811723 Disease Relevance 0.52 Pain Relevance 0.13
B induction of PRB expression through protein kinase A and CCAAT/enhancer-binding protein (CEBP) and PRA expression indirectly through MAP kinase and AP-1 activation (Figure 6).


Gene_expression (expression) of PRA
3) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2811723 Disease Relevance 0.41 Pain Relevance 0.27
There was no statistical difference between plasma levels of beta-endorphin, PRA and ACTH at rest nor in the post-exercise situation under the influence of Naltrexone.
Gene_expression (levels) of PRA in plasma
4) Confidence 0.38 Published 1989 Journal Eur J Appl Physiol Occup Physiol Section Abstract Doc Link 2555188 Disease Relevance 0.31 Pain Relevance 0.17
Several studies have indicated that in humans parturition is preceded by an increase in the expression of the progesterone dominant negative PRA relative to PRB; which leads to a functional progesterone withdrawal [9], [22]–[25].
Gene_expression (expression) of PRA associated with withdrawal
5) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2811723 Disease Relevance 0 Pain Relevance 0.12
PKC then activates MAP kinase phosphorylation, AP-1 activation and increases PRA expression (Figure 6).



Gene_expression (expression) of PRA associated with kinase c
6) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2811723 Disease Relevance 0.14 Pain Relevance 0.35
B activation led to an increase in PRA and PRB mRNA and protein expression.
Gene_expression (expression) of PRA
7) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2811723 Disease Relevance 0.15 Pain Relevance 0
Although multiple progesterone receptors have been described in the myometrium [16], [17], the two major subtypes are PRA and PRB; are encoded by a single gene and are produced independently from separate promoters [18].
Gene_expression (produced) of PRA in myometrium
8) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2811723 Disease Relevance 0 Pain Relevance 0.08
There was no statistical difference according to the treatment between the plasma levels of beta-endorphin, PRA and ACTH at rest as well as at the end of a maximal exercise.
Gene_expression (levels) of PRA in plasma
9) Confidence 0.31 Published 1989 Journal Pathol. Biol. Section Abstract Doc Link 2561015 Disease Relevance 0.15 Pain Relevance 0.30
B activation leads to an increase in Cox2 mRNA levels from 0.00054 mM at pre-labor to 0.28 µM at labor, and a 15 fold increase in PRA expression and a 4.2 fold increase in PRB expression with labor.
Gene_expression (expression) of PRA
10) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2811723 Disease Relevance 0.38 Pain Relevance 0.09
We note that the levels of PRA and Ang II measured in our septic subjects are elevated nearly two-fold compared to outpatients with risk factors for vascular disease [33,34], arguing that the acute septic state contributes to RAS activation.
Gene_expression (levels) of PRA associated with increased venous pressure under development
11) Confidence 0.25 Published 2010 Journal Crit Care Section Body Doc Link PMC2875539 Disease Relevance 1.05 Pain Relevance 0.03
In healthy humans, aliskiren of doses between 40 and 640 mg exerts a dose-dependent reduction in PRA, Ang I, and Ang II levels.
Gene_expression (levels) of PRA
12) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.09 Pain Relevance 0
The molecule is superior in reducing PRA compared with ARBs.
Gene_expression (reducing) of PRA in superior
13) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.09 Pain Relevance 0
PRA: plasma renin activity
Gene_expression (activity) of PRA in plasma
14) Confidence 0.18 Published 2003 Journal BMC Psychiatry Section Body Doc Link PMC280657 Disease Relevance 0.50 Pain Relevance 0.10
When this increase occurs during treatment with ACEIs and ARBs, the result is increased levels of PRA but during treatment with aliskiren, the effect of increased renin levels is blocked, so the levels of Ang I and Ang II, as well as PRA, are all reduced.52 The clinical trials do not report any major adverse effects of aliskiren compared with ARBs or ACEs being generally well tolerated by all patients.
Gene_expression (levels) of PRA
15) Confidence 0.16 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 1.13 Pain Relevance 0.16
Again, aliskiren at a dose of 300 mg decreases PRA in hypertensive patients by approximately 50%–80%51,52 and reduces PRA and plasma levels of Ang I and Ang II for 48 hours.53 Furthermore, urinary aldosterone was reduced at a dose of 80 mg or more, and sodium extraction was increased to 91% at a dose of 640 mg.54 Compared with valsartan, aliskiren more strongly decreases the activity of renin in the circulation and reduces the excretion of urinary aldosterone for a longer period.53,55 Following oral administration, peak plasma concentrations of aliskiren are reached within 1–3 hours.52,53,56–58 The plasma half-life of aliskiren in humans shows a slow terminal elimination at 23–70 hours59–61 and approximately 47%–51% of aliskiren is bound by plasma proteins in humans, independent of the concentration.59,62,63 Based on in vitro studies, the major enzyme responsible for its metabolism appears to be Cytochrome P450 (CYP3A4).
Gene_expression (levels) of PRA in plasma associated with hypertension
16) Confidence 0.16 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.10 Pain Relevance 0
Importantly, the rapid rise in plasma immunoreactive renin levels observed following aliskiren administration, caused by the removal of the normal feedback inhibition of Ang II on renin release, did not compromise the ability of aliskiren to provide sustained PRA inhibition and BP lowering (Wood et al 2003).
Neg (inhibition) Gene_expression (inhibition) of PRA in plasma
17) Confidence 0.12 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350136 Disease Relevance 0.08 Pain Relevance 0
However, the enzymatic activity of the renin released is blocked by aliskiren and PRA is reduced.
Gene_expression (reduced) of PRA
18) Confidence 0.10 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2952455 Disease Relevance 0.24 Pain Relevance 0
It is quickly neutralized by endogenous inhibitors, and the subsequent hourly expression of old and new renin activity (PRA) is relatively consistent during 15, 30, or 60 min incubation at 37 degrees.
Gene_expression (expression) of PRA
19) Confidence 0.04 Published 1982 Journal Clin Exp Hypertens A Section Abstract Doc Link 6756692 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox